These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 30142547)

  • 1. EGFR aptamer-conjugated liposome-polycation-DNA complex for targeted delivery of SATB1 small interfering RNA to choriocarcinoma cells.
    Dong J; Cao Y; Shen H; Ma Q; Mao S; Li S; Sun J
    Biomed Pharmacother; 2018 Nov; 107():849-859. PubMed ID: 30142547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of cellular and molecular antitumor effects upon inhibition of SATB1 in glioblastoma cells.
    Frömberg A; Rabe M; Oppermann H; Gaunitz F; Aigner A
    BMC Cancer; 2017 Jan; 17(1):3. PubMed ID: 28049521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SATB1 as oncogenic driver and potential therapeutic target in head & neck squamous cell carcinoma (HNSCC).
    Panchal O; Wichmann G; Grenman R; Eckhardt L; Kunz-Schughart LA; Franke H; Dietz A; Aigner A
    Sci Rep; 2020 May; 10(1):8615. PubMed ID: 32451408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple effects of the special AT-rich binding protein 1 (SATB1) in colon carcinoma.
    Frömberg A; Rabe M; Aigner A
    Int J Cancer; 2014 Dec; 135(11):2537-46. PubMed ID: 24729451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth.
    Xue L; Maihle NJ; Yu X; Tang SC; Liu HY
    Mol Pharm; 2018 Nov; 15(11):4801-4813. PubMed ID: 30222359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SATB1 is a Novel Molecular Target for Cancer Therapy.
    Ding M; Pan J; Guo Z; Liu Q; Yang C; Mao L
    Cancer Invest; 2018 Jan; 36(1):28-36. PubMed ID: 29381393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SATB1 promotes prostate cancer metastasis by the regulation of epithelial-mesenchymal transition.
    Mao LJ; Yang CH; Fan L; Gao P; Yang DR; Xue BX; Zheng JN; Shan YX
    Biomed Pharmacother; 2016 Apr; 79():1-8. PubMed ID: 27044805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of hepatocellular carcinoma growth using immunoliposomes for co-delivery of adriamycin and ribonucleotide reductase M2 siRNA.
    Gao J; Chen H; Yu Y; Song J; Song H; Su X; Li W; Tong X; Qian W; Wang H; Dai J; Guo Y
    Biomaterials; 2013 Dec; 34(38):10084-98. PubMed ID: 24060417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation of SATB1 promotes tumor growth and metastasis in liver cancer.
    Tu W; Luo M; Wang Z; Yan W; Xia Y; Deng H; He J; Han P; Tian D
    Liver Int; 2012 Aug; 32(7):1064-78. PubMed ID: 22583549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SATB1 and SATB2 play opposing roles in c-Myc expression and progression of colorectal cancer.
    Mansour MA; Hyodo T; Akter KA; Kokuryo T; Uehara K; Nagino M; Senga T
    Oncotarget; 2016 Jan; 7(4):4993-5006. PubMed ID: 26701851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decoy-DNA against special AT-rich sequence binding protein 1 inhibits the growth and invasive ability of human breast cancer.
    Yamayoshi A; Yasuhara M; Galande S; Kobori A; Murakami A
    Oligonucleotides; 2011; 21(2):115-21. PubMed ID: 21500976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer-targeted Nucleic Acid Delivery and Quantum Dot Imaging Using EGF Receptor Aptamer-conjugated Lipid Nanoparticles.
    Kim MW; Jeong HY; Kang SJ; Choi MJ; You YM; Im CS; Lee TS; Song IH; Lee CG; Rhee KJ; Lee YK; Park YS
    Sci Rep; 2017 Aug; 7(1):9474. PubMed ID: 28842588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-EGF Receptor Aptamer-Guided Co-Delivery of Anti-Cancer siRNAs and Quantum Dots for Theranostics of Triple-Negative Breast Cancer.
    Kim MW; Jeong HY; Kang SJ; Jeong IH; Choi MJ; You YM; Im CS; Song IH; Lee TS; Lee JS; Lee A; Park YS
    Theranostics; 2019; 9(3):837-852. PubMed ID: 30809312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A tumor-targeting cRGD-EGFR siRNA conjugate and its anti-tumor effect on glioblastoma in vitro and in vivo.
    He S; Cen B; Liao L; Wang Z; Qin Y; Wu Z; Liao W; Zhang Z; Ji A
    Drug Deliv; 2017 Nov; 24(1):471-481. PubMed ID: 28181832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SATB1 plays an oncogenic role in esophageal cancer by up-regulation of FN1 and PDGFRB.
    Song G; Liu K; Yang X; Mu B; Yang J; He L; Hu X; Li Q; Zhao Y; Cai X; Feng G
    Oncotarget; 2017 Mar; 8(11):17771-17784. PubMed ID: 28147311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SATB1 Promotes Pancreatic Cancer Growth and Invasion Depending on MYC Activation.
    Chen Z; Li Z; Li W; Zong Y; Zhu Y; Miao Y; Xu Z
    Dig Dis Sci; 2015 Nov; 60(11):3304-17. PubMed ID: 26108419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo.
    Baek SE; Lee KH; Park YS; Oh DK; Oh S; Kim KS; Kim DE
    J Control Release; 2014 Dec; 196():234-42. PubMed ID: 25450401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of human glioma U251 cells growth in vitro and in vivo by hydroxyapatite nanoparticle-assisted delivery of short hairpin RNAs against SATB1.
    Chu SH; Zhou ZM; Feng DF; Ma YB
    Mol Biol Rep; 2014 Feb; 41(2):977-86. PubMed ID: 24370885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic regulation of long noncoding RNA UCA1 by SATB1 in breast cancer.
    Lee JJ; Kim M; Kim HP
    BMB Rep; 2016 Oct; 49(10):578-583. PubMed ID: 27697109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted delivery of small interfering RNA to angiogenic endothelial cells with liposome-polycation-DNA particles.
    Vader P; Crielaard BJ; van Dommelen SM; van der Meel R; Storm G; Schiffelers RM
    J Control Release; 2012 Jun; 160(2):211-6. PubMed ID: 21983283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.